Shares of Masimo Co. (NASDAQ:MASI) have received an average recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $164.20.
A number of research firms have weighed in on MASI. BidaskClub raised Masimo from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. ValuEngine downgraded Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd.
In other news, EVP Anand Sampath sold 15,000 shares of Masimo stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $155.00, for a total value of $2,325,000.00. Following the completion of the transaction, the executive vice president now owns 27,518 shares in the company, valued at $4,265,290. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Bilal Muhsin sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $155.00, for a total value of $465,000.00. In the last ninety days, insiders sold 43,087 shares of company stock worth $6,530,607. 11.50% of the stock is owned by insiders.
Shares of Masimo stock traded up $1.76 during trading on Friday, hitting $157.37. 268,560 shares of the company’s stock traded hands, compared to its average volume of 381,884. The firm’s fifty day moving average price is $148.43 and its 200 day moving average price is $148.16. Masimo has a twelve month low of $98.23 and a twelve month high of $160.25. The company has a market cap of $8.27 billion, a PE ratio of 51.94, a PEG ratio of 2.12 and a beta of 1.15.
Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The firm had revenue of $229.01 million during the quarter, compared to analyst estimates of $221.92 million. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.71 earnings per share. As a group, research analysts predict that Masimo will post 3.17 EPS for the current year.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: Bond
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.